At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 645 enrolled
Drug / intervention
Ramucirumab +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)
In Brief
A Phase 3 clinical trial evaluating Ramucirumab, Capecitabine, and 3 other interventions for Metastatic Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma. Completed, enrolled 645 participants across 135 sites in 20 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionJan 2017
Study CompletionAug 2020
TodayJul 2026
First PostedDec 10, 2014
Enrollment StartJan 20, 2015
Primary CompletionJan 17, 2017
Study CompletionAug 14, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.6 years ago
Interventions
Ramucirumabdrug
Administered IV
Capecitabinedrug
Administered orally
Cisplatindrug
Administered IV
Placebodrug
Administered IV
Fluorouracildrug
Administered IV